Vigabatrin (Sabril&reg;) is a &gamma;-aminobutyric acid-transaminase (GABA-T) inhibitor that is effective in the treatment of certain types of drug-resistant or uncontrolled epilepsy but is known to cause microscopic vacuolation (intramyelinic edema) in the brains of treated rats, mice, and dogs. The effects of high oral doses (300 mg/kg/day) of vigabatrin administered orally to Beagle dogs were studied during treatment weeks 1-12 and recovery weeks 13, 14, 16, 20, 24, and 28. Emesis, loose stools, and anorexia and 3 drug-related deaths were observed during the first 4 wk of treatment but were virtually nonexistent thereafter because of adaptation to the drug aided by food supplementation. In more sensitive areas of the brain (columns of the fomix, thalamus, and hypothalamus), microscopic quantitative differences between background vacuolation in controls and drug-related vacuolation in treated dogs could be delineated after 4 wk, generally reached highest levels of severity between 8 and 12 wk, and were reversible upon cessation of dosing. Inhibition of brain GABA-T and elevation of brain GABA were noted after 1 wk of treatment. During the course of treatment vigabatrin ranged between 4-17 nmol/ml (plasma) and 42-1,570 nmol/ml [cerebrospinal fluid (CSF)] while CSF GABA concentrations were 4-32 nmol/ml (treated dogs) and 0.1-0.6 nmol/ml (control dogs). Although the cause of vigabatrin-induced microvacuolation is unknown, the results of the study demonstrated that GABA-T inhibition with subsequent GABA elevation occurred within the first week of treatment and was followed by the onset of detectable microvacuolation several weeks later.
INTRODUCTION
Vigabatrin [4- amino-5-hexenoic acid, ~y-vinyl y-aminobutyric acid (GABA), Sabril@] is an enzyme-activated irreversible inhibitor of GABA transaminase (GABA-T) (18, 19) , the enzyme responsible for the degradation of GABA, a major inhibitory neurotransmitter. Because vigabatrin-induced elevation of brain GABA has been shown to prevent seizures in experimental animal models (24-26, 31 ), testing has been extended to human patients with difficult to control epilepsy. Currently, vigabatrin has demonstrated efncacy in patients with uncontrolled or drug-resistant focal epilepsy with complex partial seizures (3, 12, 29) .
Toxicity studies with vigabatrin have demonstrated microscopic brain vacuolation, most notably in white matter tracts, as the main toxic effect in mice, rats, and dogs given dosages of 30-300 mg/ kg/day in subacute and chronic tests (1, 4, 5, 9, 10, 32, 37) . Cynomolgus monkeys treated with 300 mg/ kg/day for 16 mo exhibited minimal microvacuolation, which was considered equivocal since it was not noticeably different from background observed in controls (4, 9, 10) . Other monkeys receiving 50 or 100 mg/kg/day for up to 6 yr did not exhibit any adverse effects (9) . Ultrastructural examination of the brains from treated rats (5, 9) and dogs (1) demonstrated that the microvacuoles occurred as a result of splitting of the outer lamellar layers of the myelin sheaths at the intraperiod line, findings compatible with intramyelinic edema.
The presence of intramyelinic edema during preclinical animal toxicity studies ofvigabatrin has created safety concerns for human patients. Because of these concerns considerable effort has been made to develop noninvasive methods that can detect the presence of this intramyelinic edema in dogs. Recent, biweekly electrophysiological testing of dogs has shown that 300 mg/kg/day of vigabatrin given for 15 wk caused significant changes in conduction of myelinated fiber tracts of the central nervous system characterized by slowing of somatosensory and 0192-6233193~3.00+~0.00 visual evoked potentials (32) . Earliest changes in these evoked potentials appear to occur between 4 and 6 wk; however, statistically significant differences were not evident until 8-10 wk. In these same chronically administered dogs, magnetic resonance imaging (MRI) of brains taken at the end of the treatment period detected changes both in vivo and ex vivo in areas (thalamus, hypothalamus, and columns of the fomix) where intramyelinic edema was prominent histologically (37) .
The purpose of the present investigation was to determine microscopically the time-course for the onset and reversibility of brain vacuolation in vigabatrin-treated dogs with particular emphasis on structures demonstrating marked sensitivity. This was done so that the time sequence of these changes can be correlated with evoked potential and MRI changes. Related efi°ects including clinical signs, brain biochemistry, and pharmacokinetic data were also evaluated. The results of ex vivo MRI scans of these same brains will be reported elsewhere (28) .
MATERIALS AND METHODS
Experimental Animals. Fifty-four male and 54 female Beagles (Haiqijon Research Products, Inc., Kalamazoo, MI) identified by chest tattoo, collar tag, and cage card were individually housed in fenced runs in light-and temperature-controlled rooms and conditioned to their laboratory environment for a minimum of 37 days. Each animal was fed ad libitum dry dog food (Certified Canine Diet@ No. 5007, Purina Mills, Richmond, IN) or if they became anorexic while on treatment, canned dog food (Ken -L-Ration &reg; , The Quaker Oats Company, Chicago, IL). Drinking water (deionized) was provided continuously by means of automatic waters. All animal care and procedures were in conformity with the NIH Guide for the Care and Use of laboratory Animals (7) .
Experimental Design. Eighteen experimental groups were created by assigning 2 control dogs ( 1 male, 1 female) and 4 dogs treated with 300 mg/kg/ day (2 males, 2 females) to each group. The dose of 300 mg/kg, which was given daily in gelatin capsules, was chosen because it has previously been shown to cause marked vacuolation in the brains of dogs after 3 months of treatment (1, 9, 32) . To achieve representative groups, animal assignments were based on history, sex, weight, and pretest clinicopathological data. A group of dogs was necropsied weekly during treatment period weeks 1-12 and after recovery weeks 13, 14, 16, 20, 24, and 28. Clinical Observations. The dogs were observed at least twice daily for any physical abnormality and clinical signs. Physical examinations were also given pretest and prior to scheduled necropsies. Clinical Pathology. Blood samples from fasted dogs were collected by venipuncture for hematology and clinical chemistry determinations during pretest and before sacrifice. Hematological parameters consisted of erythrocyte counts, leukocyte counts, platelet counts, hematocrit, and hemoglobin (determined by an Ortho ELT-8 Hematology Analyzer, Ortho Diagnostic Systems, Westwood, MA); morphological and differential evaluation of erythrocytes (nucleated cells, reticulocytes, Heinz bodies) performed manually using blood smears; and prothrombin and partial thromboplastin times (measured by an Electra 600 Automatic Coagulation Timer&reg;, Medical Laboratory Automation, Inc., Pleasantville, NY). Serum chemistry measurements (Dacos Analyzer&reg;, Coulter Electronics, Inc., Hialeah, FL) included: chloride, carbon dioxide, total and direct bilirubin, total protein, albumin, calcium, inorganic phosphorus, glucose, blood urea nitrogen, alkaline phosphatase, aspartate aminotransferase (AST), alanine aminotransferase (ALT), sodium, potassium, cholesterol, triglycerides, and creatinine.
Pathology. With the exception of 2 dogs that died on study, all dogs were sacrificed under anesthesia (Surital ~ , Parke-Davis, Division of Warner-Lambert Co., Morris Plains, NJ) and then exsanguinated prior to necropsy. Immediately, the dorsal calvarium was removed exposing the brain. After a small specimen of brain tissue (left temporal lobe) was removed for biochemical analysis, the remaining intact brain was promptly placed in 20% buffered formalin. The cervical and lumbar spinal cord segments, dorsal root ganglion, stellate ganglion, caudal cervical ganglion, celiac ganglion, and peripheral nerve (sciatic nerve) were then dissected and placed in 20% formalin while both eyes were placed in Davidson's fixative. Following fixation, tissue specimens were processed, embedded in paraffin, sectioned at 5-6 mm, mounted on glass slides, and stained with hematoxylin and eosin for microscopic examination. To insure a comprehensive evaluation of the brain, coronal cross sections were made of the following levels: (A) optic chiasma; (B) hypothalamus, columns of the fornix, and optic tract; (C) lateral geniculate body and hippocampus; and (D) cerebellum containing roof nuclei. Independent microscopic evaluation by 2 pathologists was conducted in a blinded fashion since tissues were coded by a designated histology technician so that the identities of the dogs were unknown as to actual dog study number, dose, and treatment/recovery week. Since the expected neuropathology of vigabatrintreated dogs is primarily vacuolation, special detail was given to defining and grading this lesion. Vacuoles lined by endothelial cells (dilated capillaries) were eliminated from consideration; only sharply outlined vacuoles were evaluated. Severity grade of vacuolation based on percentage brain structure involvement (0, G 1%; 1, 1-20%; 2, 21-40%; 3, 41-60% ; 4, 61-80%; and 5, >81%) as well as distribution (focal, multifocal, or diffuse) were recorded.
After a consensus determination of all vacuolation findings by the two pathologists, the results were decoded and properly identified. Study findings were then retabulated as to actual dog and treatment/ recovery week. All other analyses (see below) were also done in a blinded fashion.
Concentrations of Plasma Vigabatrin and Cerebrospinal Fluid Vigabatrin and GABA. Prior to a scheduled necropsy (24 hr postdosing), blood (5-7 ml) was collected, transferred to a glass tube containing EDTA (Vacutainers ~ , Becton-Dickinson and Co., Rutherford, NJ) and placed in ice until centrifuged a short time later. Following centrifugation, plasma was pipetted into small screw-cap scintillation tubes, frozen, and temporarily stored at -70°C. Plasma vigabatrin levels were determined using a high-performance liquid chromatography (HPLC) method with fluorometric detection (33) for the purpose of establishing the degree of absorption of the drug.
Cerebrospinal fluid (CSF) was aspirated (21 -gauge needle/3-cc syringe) 24 hr postdosing from the cistema magna of the anesthetized dogs just prior to necropsy. CSF vigabatrin and GABA concentrations were determined by gas chromatographic (GC)/ positive chemical ionization mass spectrometry (MS) as previously described (9) . GABA conjugates were acid hydrolyzed prior to GC/MS analysis so that total GABA (free and conjugated) could be determined. CSF GABA has been shown to correlate well with changes in brain GABA concentrations (2, 13) while CSF vigabatrin indicates drug passage through the blood-brain barrier.
Analysis of Brain Tissue for GABA, GABA-T, and GAD. A superficial section (less than 0.2 g) of the left temporal lobe of the cerebrum was removed within 3-4 min after exsanguination of anesthetized dogs and quickly frozen in liquid nitrogen. These samples were stored frozen at -80°C until assayed for GABA, GABA-T, and GAD (glutamate decarboxylase) according to methods previously used for brains of mice, rats, and monkeys (18) (19) (20) (21) . GAD is the enzyme responsible for the synthesis of GABA in GABAergic neurons (12, 20) . 
RESULTS

Clinical Observations
Within the first week of treatment most treated dogs became anorexic. Between the second and fourth week of dosing, 2 treated dogs died and 1 was sacrificed because of its moribund condition.
During this period of treatment, clinical pathological evaluation of many of the sacrificed dogs demonstrated increased cholesterol and triglycerides. These findings are likely related to anorexia, which appeared to be a major contributory factor in the cause of death or morbidity. To encourage eating, anorexic dogs were first fed canned dog food. However, a liquid slurry of canned dog food was given by gavage to any dog not forming stools, not eating within a 24-hr period, and/or losing body weight (~: 10%). After forced feeding began, no further deaths occurred. Additional sporadic observations included emesis, soft stools, and diarrhea, which may have been treatment related. After about 1 mo of dosing, the clinical observations became less frequent and severe. By the end of treatment and during 1-16 wk of recovery, no signs of toxicity were noted. 
Clinical Pathology
Erythrocytic parameters were slightly affected in 5 treated dogs between 5 wk of treatment and 2 wk of recovery as indicated by slightly lower total erythrocyte counts (<5.0 x 1 O6Imm3), hemoglobin ( < 14.0 g/dl), and hematocrit ( < 40%). Leukocyte counts, coagulation times (prothrombin; partial thromboplastin), and platelet counts were within normal limits.
Serum ALT values were generally decreased for the treated dogs for the 12 wk of vigabatrin administration. This effect is most likely due to nonspecific inhibition of other transaminase enzymes and is consistent with previous observations of transitory declines in the ALT enzyme in dogs and monkeys treated with ~50 mg/kg/day of the drug for at least 3 mo (9). Slightly elevated cholesterol levels (216-279 mg/ml) were also detected in 50% of the dogs during the first 3 wk of treatment, possibly indicating fat mobilization in response to drug-induced anorexia. Increased cholesterol values were infrequent thereafter. All other clinical chemistry parameters appeared unaffected by treatment.
Histopczthology
Like previous dog studies (4, 9, 10), varying degrees of vacuolation (intramyelinic edema) were observed in selected tracts of the brain (Table I) without any obvious sex differences. Many of the affected areas were present in section through the optic chiasma (Fig. 1) . The progression of the vacuolation is best illustrated by the columns of the fornix, a tract very susceptible to vigabatrin effects (Fig. 2) . When the columns of the fornix were analyzed, the amount of drug-related vacuolation was first statistically different (p s 0.05) from controls after 4 wk of treatment ( Fig. 3) . Mean values for drug-induced vacuolation of the hypothalamus first exceeded background threshold (0-2.0 severity grade) after 4 wk while the thalamus did not exceed background until after 5 wk. These findings led to the general conclusion that drug-induced vacuolation in more sensitive tracts could not be delineated from normal background until after 4 wk of treatment had been completed. In comparison, no difference was noted until after 5 wk, when all evaluated sites were analyzed collectively (Fig. 3 ). The severity of vacuolation continued to increase during the treatment period with maximum levels being found in the thalamus (3.3 mean severity grade) and columns of the fornix (5.0 mean severity grade) at week 11 and hypothalamus (3.3 mean severity grade) at week 8. In less sensitive myelinated tracts such as the optic tract, there was little difference between vacuolation in control and treated dogs ( Table I) . The spinal cord, peripheral nervous system (sciatic nerve and dorsal root, stellate, caudal cervical, and celiac ganglia), and eyes were unaffected by treatment.
The average severity grade of vacuolation among the various affected sites progressively declined beginning 1 wk postdosing ( Figs. 3 and 4) . recovery period. These findings indicate that vigabatrin-induced vacuolation was reversible in the dog and are consistent with previous observations (9) .
Concentrations of Plasma Vigabatrin and CSF Vigabatrin and GABA (24 hr Postdosing)
Steady-state plasma vigabatrin concentrations ranged between 4 and 17 nmol/ml during the 12 wk of treatment and were generally slightly higher in males (Fig. 4) . After 1 wk of recovery (week 13), concentrations were below the limit of quantitation (1.6 nmol/ml). CSF vigabatrin concentrations reached steady-state levels after 1 wk of treatment and varied between 8 to 117 times higher (42-1,57t1 nmol/ml) than in plasma, reflecting slower clearance ( Fig. 4 ). CSF total (free and conjugated) GABA concentrations for individual treated dogs were 4-32 nmol/ml during treatment compared to 0.1-0.6 nmol/ml in controls (Fig. 4) . Concentrations returned to control levels following 1 wk of recovery from dosing.
There was no sampling of the 2 dogs that died. However, plasma and CSF samples were obtained from 1 male dog that was sacrificed moribund on day 24, approximately 27 hr after dosing. Plasma concentration of vigabatrin in this dog was 93 nmol/ ml, which was the highest value detected in any of the treated dogs. CSF concentrations of vigabatrin and GABA were also markedly elevated, being 628 and 24.4 nmol/ml, respectively. The additional observation that mean plasma and CSF vigabatrin as well as CSF GABA were elevated to their highest levels during the first few weeks of treatment suggests that the drug did cause the anorexia, which led to the generalized toxicity. The fact that force feeding allowed the dogs to overcome these effects and for the blood levels to decline somewhat indicates that the dogs were able to adapt to the high dose of 300 mg/kg/day of vigabatrin.
Analysis of Brain GABA, GABA-T, and GAD After 1 wk of dosing, brain GABA levels were markedly elevated while GABA-T and GAD values were noticeably lower in all treated dogs (Fig. 5 ). GABA-T activity did not decrease noticeably after the first 2 wk of treatment. This may explain why brain GABA levels, which reached highest levels after 2 wk of treatment, did not increase further.
Following cessation of dosing, brain GABA-T and GAD activities and GABA levels in vigabatrintreated dogs became indistinguishable from controls after 1 wk and remained so during the remainder of the recovery period (Fig. 5 ). 35 and 50 mg/kg/day, have proven to be very effica= cious in the treatment of human patients with a history of uncontrolled or drug-resistant epilepsy (3, 12, 29) . Currently, there is no evidence of alterations in clinical (3, 11, 12, 22, 29, 35, 36) , electrophysiological (14) , and psychometric and psychophysiological tests (30) , and brain histology (6, 10, 12, 15, 27) in these patients. However, findings in preclinical animal studies have caused safety concerns about long-term clinical use of vigabatrin. These studies demonstrated that microscopic brain vacuolation (intramyelinic edema) developed in a doserelated (50-300 mg/kg/day) manner in treated rats, mice, and dogs but was equivocal in monkeys given 300 mg/kg/day (1, 5, 9, 10) . Similar vacuolation has been detected in animals treated with other GABA-T inhibitors including ethanolamine-osulfate (16) , °y-allenyl GABA (9) , and BW 357U (9) . The issue of safety has led to an ongoing effort to validate noninvasive procedures to detect this vacuolation. However, the precise time when vigabatrin-induced brain vacuolation develops has not been established. The principal objective of the present investigation was to establish the time-course for the onset and reversibility of brain vacuolation using the dog. It is a species very susceptible to vigabatrin's effects and is a relatively good model to study evoked potentials (1, 32) and MRIs (37) . A high dose of 300 mg/kg/day was chosen to insure that detectable changes in both brain histology and biochemistry would be present after 12 wk of treat- (9, 32) . To avoid bias, the histological evaluation of dog brains was conducted in a blinded fashion so that the dose and week of treatment or recovery were unknown to the reviewing pathologists. A second objective was to attempt to correlate The first indication of drug effects was clinical signs of anorexia and emesis seen during the first week of treatment. At the end of 1 wk of dosing, plasma and CSF vigabatrin as well as CSF GABA concentrations 24 hr postdosing were at study-state levels. Brain biochemistry changes were also apparent after the first week. Lowered GAD activity was most likely due to feedback inhibition of new enzyme synthesis because vigabatrin does not inhibit this enzyme in vitro (18) (19) (20) . Since reduced GAD activity should decrease GABA synthesis, the elevated GABA levels were indicative of vigabatrin's effect on prolonging GABA degradation by its profound inhibition of GABA-T. Previous studies have indicated that GABA-T inhibitors must inhibit enzyme levels by about 50% in order to significantly elevate GABA in rodents (8, 17) . Such was the effect in the dogs after dosing vigabatrin for 1 wk. After reaching highest levels after 2 wk of treatment, GABA and GABA-T values were detected at slightly lower but relatively constant levels for the remainder of treatment. By the fourth week of treatment, microscopic differences between background vacuolation and drug-related vacuolation were apparent and continued to increase until plateauing in severity between 8 and 12 wk of dosing. The magnitude and progression of vacuolation appeared to be directly related to the sensitivity of the affected tract or area of the brain. At approximately the same time interval of 4 wk, clinical signs began to dissipate in frequency and severity, probably the result of adaptation to the drug as suggested by trends in both brain biochemistry and pharmacokinetics. A recent investigation of dogs treated with the 300mg/kg/day dose of vigabatrin suggested that slowing of somatosensory and visual-evoked potentials began at week 6 and weeks 4-6, respectively. However, significant differences based on group averages were not observed until 8-10 wk of dosing (32) . MRI changes were also detectable after 4-7 wk (37) . Thus, functional disturbances of the vigabatrin-treated dog brain appear to occur at about the same time or slightly after the intramyelinic edema becomes distinguishable from the background vacuolation of controls. All of these drug-induced effects are reversible upon cessation of dosing, although brain histology was last to return to normal.
DISCUSSION
Doses of vigabatrin, generally ranging between
Although the cause of vigabatrin-induced microvacuolation is unknown, similar neuropathology has been reported with other GABA-T inhibitors such as ethanolamine-o-sulfate (16), y-allenyl GABA (9), and BW 357U (9), suggesting that elevated GABA levels may be involved in the pathogenesis. In the present study, changes in brain biochemistry did not correlate simultaneously with the appearance or regression of the intramyelinic edema. These results suggest that elevations in brain GABA may be responsible for the formation of intramyelinic edema but that additional mechanisms may be involved in its development. The absence of vacuolation in the retina, optic nerve, spinal cord, and peripheral nervous system including sciatic nerve and both somatic and autonomic ganglia is consistent with findings of previous animal studies that vigabatrin's neuropathology is confined to the brain (4, 9, 10) .
